Ustekinumab vs Upadacitinib for Refractory Crohn's Disease
Treatments studied
Part of Digestive system, Immune system & allergy clinical trials.
This study compares two medicines, ustekinumab and upadacitinib, to see which works better for people with Crohn's disease that hasn't improved with other treatments. Both are taken as injections or pills and aim to reduce inflammation and help you feel better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You have been diagnosed with Crohn's disease for at least 3 months and have active ulcers seen on a colonoscopy.
- You have tried at least one anti-TNF medicine (like infliximab or adalimumab) and it didn't work or you couldn't take it.
- You are not currently using certain other Crohn's medicines (like azathioprine or methotrexate) within 4 weeks of starting the study.
- You do not have active infections like tuberculosis, hepatitis, or HIV, and you have had a recent negative TB test.
- You have not had bowel surgery in the last 6 months or a recent hospitalization for a bowel blockage.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a combination of two drugs (upadacitinib and ustekinumab) works better than a higher dose of ustekinumab alone for people with active Crohn's disease that hasn't responded well to previous treatments.
This study tests two oral/ injectable medicines (upadacitinib and risankizumab) in adults with moderate-to-severe Crohn's who have already tried a TNF-blocker. It aims to see how well these treatments work in everyday practice.
This trial tests two different medicines, infliximab and upadacitinib, to see which works better for people with severe ulcerative colitis that hasn't improved after 3 days of IV steroids. The goal is to find the best rescue option to help you feel better and avoid surgery.
This study compares two medications—upadacitinib and infliximab—as second-line treatments for acute severe ulcerative colitis (a serious flare of inflammatory bowel disease). The trial will help doctors understand which treatment works better when standard first-line therapy hasn't controlled the inflammation.
This study compares an existing UC medication (infliximab) with a newer one (ustekinumab) and a combination of both. The goal is to see which works best for moderate to severe UC when other treatments have failed.
This study tests a medication called upadacitinib for people with inflammatory bowel disease (ulcerative colitis or Crohn's). The goal is to see how well it works and if it's safe.
Hear when a new Crohn's Disease Aggravated trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.